FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892494577> ?p ?o ?g. }

• W2892494577 endingPage "88" @default.
• W2892494577 startingPage "85" @default.
• W2892494577 abstract "Monoclonal antibodies that block the programmed death-1 (anti-PD-1) or cytotoxic T-lymphocyte antigen-4 (CTLA-4) immune checkpoint receptors (pembrolizumab, nivolumab, ipilimumab, or the combination of nivolumab with ipilimumab) are approved treatment option for patients with advanced melanoma. Over half of all patients are refractory to these immunotherapies and are in need of alternative or complementary treatment options. Talimogene laherparepvec (T-VEC) is a first-in-class intralesionally delivered oncolytic immunotherapy, which has proven efficacy in the treatment of advanced melanoma. A proportion of patients treated with T-VEC will benefit from an abscopal response of noninjected metastases indicative of a systemic antitumor immune response elicited by the intratumoral injections. At present it remains unknown whether the systemic antitumor responses elicited by T-VEC are nonredundant with immune-checkpoint blockade. Recent data on potential synergy between T-VEC and both PD-1 and CTLA-4 blockade suggest that the mechanism of action may be complementary. We report on the successful treatment with intralesional T-VEC of two female patients with locoregionally advanced BRAF V600 wild-type melanoma who previously progressed on anti-PD-1 and anti-CTLA-4 inhibitors." @default.
• W2892494577 created "2018-10-05" @default.
• W2892494577 creator A5002423487 @default.
• W2892494577 creator A5008459225 @default.
• W2892494577 creator A5041521047 @default.
• W2892494577 creator A5049720337 @default.
• W2892494577 creator A5063562171 @default.
• W2892494577 creator A5071747885 @default.
• W2892494577 creator A5072372960 @default.
• W2892494577 creator A5082449165 @default.
• W2892494577 creator A5082778229 @default.
• W2892494577 creator A5085414749 @default.
• W2892494577 date "2019-02-01" @default.
• W2892494577 modified "2023-09-23" @default.
• W2892494577 title "Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma" @default.
• W2892494577 cites W2086591619 @default.
• W2892494577 cites W2096322385 @default.
• W2892494577 cites W2109274792 @default.
• W2892494577 cites W2137128541 @default.
• W2892494577 cites W2148576689 @default.
• W2892494577 cites W2152897456 @default.
• W2892494577 cites W2165320653 @default.
• W2892494577 cites W2309483848 @default.
• W2892494577 cites W2427476638 @default.
• W2892494577 cites W2473956396 @default.
• W2892494577 cites W2512178424 @default.
• W2892494577 cites W2555619826 @default.
• W2892494577 cites W2588146309 @default.
• W2892494577 cites W2589751944 @default.
• W2892494577 cites W2617516738 @default.
• W2892494577 cites W2626018034 @default.
• W2892494577 cites W2736194991 @default.
• W2892494577 cites W2750781282 @default.
• W2892494577 cites W2803619375 @default.
• W2892494577 doi "https://doi.org/10.1097/cmr.0000000000000501" @default.
• W2892494577 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30211812" @default.
• W2892494577 hasPublicationYear "2019" @default.
• W2892494577 type Work @default.
• W2892494577 sameAs 2892494577 @default.
• W2892494577 citedByCount "14" @default.
• W2892494577 countsByYear W28924945772019 @default.
• W2892494577 countsByYear W28924945772020 @default.
• W2892494577 countsByYear W28924945772021 @default.
• W2892494577 countsByYear W28924945772022 @default.
• W2892494577 countsByYear W28924945772023 @default.
• W2892494577 crossrefType "journal-article" @default.
• W2892494577 hasAuthorship W2892494577A5002423487 @default.
• W2892494577 hasAuthorship W2892494577A5008459225 @default.
• W2892494577 hasAuthorship W2892494577A5041521047 @default.
• W2892494577 hasAuthorship W2892494577A5049720337 @default.
• W2892494577 hasAuthorship W2892494577A5063562171 @default.
• W2892494577 hasAuthorship W2892494577A5071747885 @default.
• W2892494577 hasAuthorship W2892494577A5072372960 @default.
• W2892494577 hasAuthorship W2892494577A5082449165 @default.
• W2892494577 hasAuthorship W2892494577A5082778229 @default.
• W2892494577 hasAuthorship W2892494577A5085414749 @default.
• W2892494577 hasConcept C121332964 @default.
• W2892494577 hasConcept C126322002 @default.
• W2892494577 hasConcept C142424586 @default.
• W2892494577 hasConcept C143998085 @default.
• W2892494577 hasConcept C170493617 @default.
• W2892494577 hasConcept C203014093 @default.
• W2892494577 hasConcept C2777658100 @default.
• W2892494577 hasConcept C2777701055 @default.
• W2892494577 hasConcept C2778468042 @default.
• W2892494577 hasConcept C2780030458 @default.
• W2892494577 hasConcept C2780057760 @default.
• W2892494577 hasConcept C2780851360 @default.
• W2892494577 hasConcept C2781274730 @default.
• W2892494577 hasConcept C2781433595 @default.
• W2892494577 hasConcept C502942594 @default.
• W2892494577 hasConcept C71924100 @default.
• W2892494577 hasConcept C82210918 @default.
• W2892494577 hasConcept C87355193 @default.
• W2892494577 hasConcept C8891405 @default.
• W2892494577 hasConceptScore W2892494577C121332964 @default.
• W2892494577 hasConceptScore W2892494577C126322002 @default.
• W2892494577 hasConceptScore W2892494577C142424586 @default.
• W2892494577 hasConceptScore W2892494577C143998085 @default.
• W2892494577 hasConceptScore W2892494577C170493617 @default.
• W2892494577 hasConceptScore W2892494577C203014093 @default.
• W2892494577 hasConceptScore W2892494577C2777658100 @default.
• W2892494577 hasConceptScore W2892494577C2777701055 @default.
• W2892494577 hasConceptScore W2892494577C2778468042 @default.
• W2892494577 hasConceptScore W2892494577C2780030458 @default.
• W2892494577 hasConceptScore W2892494577C2780057760 @default.
• W2892494577 hasConceptScore W2892494577C2780851360 @default.
• W2892494577 hasConceptScore W2892494577C2781274730 @default.
• W2892494577 hasConceptScore W2892494577C2781433595 @default.
• W2892494577 hasConceptScore W2892494577C502942594 @default.
• W2892494577 hasConceptScore W2892494577C71924100 @default.
• W2892494577 hasConceptScore W2892494577C82210918 @default.
• W2892494577 hasConceptScore W2892494577C87355193 @default.
• W2892494577 hasConceptScore W2892494577C8891405 @default.
• W2892494577 hasIssue "1" @default.
• W2892494577 hasLocation W28924945771 @default.
• W2892494577 hasLocation W28924945772 @default.
• W2892494577 hasOpenAccess W2892494577 @default.

• next